FDA clears Solventum's combined Restrata Matrix and V.A.C. Therapy

October 19, 2026 4:05 PM

Solventum (NYSE: SOLV) announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the combined use of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found